Search This Blog

Friday, August 31, 2018

BeiGene says NMPA of China accepts NDA for tislelizumab


BeiGene announced that the National Medical Products Administration of China has accepted the new drug application for tislelizumab, an investigational anti-PD-1 antibody, as a potential treatment for patients with relapsed/refractory classical Hodgkin’s lymphoma.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.